Envista vs Teleflex
NVST and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVST and TFX compare
Teleflex is the larger company, worth 1.7 times as much as Envista ($6.6B against $3.9B).
On earnings, Envista is cheaper: it trades at 6.3× trailing earnings, against 18.8× for Teleflex.
Teleflex grew revenue faster over the last twelve months (20.9% versus 9.8% for Envista).
Envista keeps more of each dollar of sales as profit, with a net margin of 22.0% compared with 13.5% at Teleflex.
Teleflex pays a dividend yielding 0.88%; Envista does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVST | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $3.9B | $6.6B |
| Share price | $24.49 | $155.10 |
| Change, 1 year | 21.7% | 39.1% |
| Change, 5 years | −41.8% | −51.4% |
| Beta (5Y) | 0.94 | 0.82 |
| Employees | 12K | 16K |
| StockData Score | ||
| Total score | 17 | 17 |
| Valuation score | 6 | 6 |
| Growth score | 3 (better) | 2 |
| Performance score | 5 (better) | 3 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 6.3× (better) | 18.8× |
| P/S | 1.4× (better) | 2.9× |
| P/B | 1.3× (better) | 1.9× |
| EV/EBITDA | 5.0× (better) | 18.4× |
| P/FCF | 16.3× (better) | 27.0× |
| FCF yield | 6.2% (better) | 3.7% |
| Fair value | $94.47 | $215.29 |
| Margin of safety | 74.1% (better) | 28.0% |
| Growth | ||
| Revenue growth (TTM) | 9.8% | 20.9% (better) |
| Revenue growth, 5Y average | 7.1% (better) | −4.7% |
| Net income growth (TTM) | 4041% | – |
| EPS growth (TTM) | 4200% | – |
| EPS growth, 5Y average | 7.0% | – |
| Profitability | ||
| Gross margin | 55.9% | 58.3% (better) |
| Operating margin | 25.4% (better) | 9.4% |
| Net margin | 22.0% (better) | 13.5% |
| FCF margin | 8.4% | 10.8% (better) |
| Return on equity | 20.5% (better) | 8.3% |
| Return on invested capital | 20.0% (better) | 3.1% |
| Financial health | ||
| Debt / equity | 0.46 (better) | 0.46 |
| Net debt / EBITDA | 0.32 (better) | 2.82 |
| Interest coverage | – | 2.1× |
| Current ratio | 2.45 (better) | 2.01 |
| Altman Z-score | 2.17 (better) | 2.02 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.88% |
| Payout ratio | – | 19.3% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | 3.5% | 8.4% (better) |
| Shareholder yield | 3.5% | 9.3% (better) |
| Ownership | ||
| Held by institutions | 118% | 113% |
| Held by insiders | 0.85% | 0.73% |
| Insider net buying, 12 months | −$510K | – |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 6.1% | 9.7% |
Go deeper
- NVST stock overview
- NVST income statement
- NVST valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.